0.6187 -0.008 (-1.21%) | 02-19 12:53 | |||||||||||||
|
|
Short term | ![]() |
|||
Mid term | ![]() ![]() ![]() |
|||
Targets | 6-month : | 0.83 ![]() |
1-year : | 0.94 ![]() |
Resists | First : | 0.71 ![]() |
Second : | 0.8 ![]() |
Pivot price | 0.65 ![]() |
|||
Supports | First : | 0.57 | Second : | 0.47 |
MAs | MA(5) : | 0.63 ![]() |
MA(20) : | 0.67 ![]() |
MA(100) : | 0.99 ![]() |
MA(250) : | 1.67 ![]() |
|
MACD | MACD : | -0.1 ![]() |
Signal : | -0.1 ![]() |
%K %D | K(14,3) : | 27.7 ![]() |
D(3) : | 27.8 ![]() |
RSI | RSI(14): 34 ![]() |
|||
52-week | High : | 3.79 | Low : | 0.57 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ OVID ] has closed above bottom band by 24.9%. Bollinger Bands are 38.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
If tomorrow: | Open lower | Open higher |
High: | 0.67 - 0.68 | 0.68 - 0.68 |
Low: | 0.61 - 0.62 | 0.62 - 0.62 |
Close: | 0.62 - 0.63 | 0.63 - 0.63 |
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
Tue, 18 Feb 2025
Dup15q Syndrome Market Expected to rise, 2032 | Ovid - openPR
Thu, 13 Feb 2025
Ovid Therapeutics faces Nasdaq delisting over share price - Investing.com
Thu, 13 Feb 2025
Ovid Therapeutics Inc - Receives Nasdaq Notice For Minimum Bid Price Non-Compliance - Marketscreener.com
Wed, 12 Feb 2025
Ovid stock plunges to 52-week low, touches $0.59 amid downturn - MSN
Wed, 05 Feb 2025
Healthcare Spotlight: Ovid Therapeutics Takes Center Stage at Major Oppenheimer Conference - StockTitan
Wed, 05 Feb 2025
Ovid Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference - GlobeNewswire
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 0 (M) |
Shares Float | 71 (M) |
Held by Insiders | 4.645e+007 (%) |
Held by Institutions | 15.8 (%) |
Shares Short | 692 (K) |
Shares Short P.Month | 0 (K) |
EPS | -6.506e+007 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 0 |
Profit Margin | 0 % |
Operating Margin | -7 % |
Return on Assets (ttm) | 645 % |
Return on Equity (ttm) | -36.1 % |
Qtrly Rev. Growth | 631700 % |
Gross Profit (p.s.) | 195.66 |
Sales Per Share | -122.04 |
EBITDA (p.s.) | 2.10567e+006 |
Qtrly Earnings Growth | -0.5 % |
Operating Cash Flow | 0 (M) |
Levered Free Cash Flow | -58 (M) |
PE Ratio | -0.01 |
PEG Ratio | 0 |
Price to Book value | 0 |
Price to Sales | -0.01 |
Price to Cash Flow | 0.17 |
Dividend | 0 |
Forward Dividend | 883740 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |